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Abstract
Background: Bacteria excrete costly toxins to defend their ecological niche. The evolution of such antagonistic
interactions between individuals is expected to depend on both the social environment and the strength of
resource competition. Antagonism is expected to be weak among highly similar genotypes because most
individuals are immune to antagonistic agents and among dissimilar genotypes because these are unlikely to be
competing for the same resources and antagonism should not yield much benefit. The strength of antagonism is
therefore expected to peak at intermediate genetic distance.
Results: We studied the ability of laboratory strains of Pseudomonas aeruginosa to prevent growth of 55 different
clinical P. aeruginosa isolates derived from cystic fibrosis patients. Genetic distance was determined using genetic
fingerprints. We found that the strength of antagonism was maximal among genotypes of intermediate genetic
distance and we show that genetic distance and resource use are linked.
Conclusions: Our results suggest that the importance of social interactions like antagonism may be modulated by
the strength of resource competition.
Background
The production by microorganisms of proteinaceous
anticompetitor toxins such as bacteriocins is often cited
as a good example of an antagonistic trait [1]. The evo-
lution of antagonistic interactions is difficult to under-
stand because they directly harm both actor and
recipient. At the level of an individual gene, this appar-
ent paradox can be readily resolved using the framework
of inclusive fitness [2], which shows that antagonistic
interactions can evolve provided they produce a net
benefit to actors, even if the act of antagonism itself is
costly.
Bacteriocin production has the hallmark of a classic
antagonistic trait that can evolve through its effects on
inclusive fitness. Bacteriocins are produced by nearly all
bacteria and are considered the main agents in direct
antagonistic interactions between and within bacterial
species [3-6]. The production of bacteriocins is costly,
both in terms of the energy diverted away from other
functions such as growth and, in Gram-negatives at
least, because bacteriocin-producing cells release their
bacteriocins through lysis and so cause cell death [5].
Importantly, cells that are isogenic to the producing
strain (typically a small fraction of cells within a popula-
tion produce bacteriocins at any given time) are
immune to the bacteriocin, usually via an immunity pro-
tein, and so gain a benefit from bacteriocin production
from clone-mates. It has also been repeatedly noted that
bacteriocins are highly specific in their action, being
active primarily against genetically distinct members of
the same species or species closely related to the produ-
cing strain [3,7].
We suggest that the mechanism underlying the varia-
tion in the antagonistic effects of toxins like bacteriocins
is caused by intraspecific resource competition. We
expect that the ability of these toxins to remove compe-
titors, and so free up resources, would evolve to be max-
imal when resource competition is strongest among
genetically distinct individuals. The logic behind this is
straightforward. Toxin production should not be
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favoured when competing with genetically identical
clones because there is no fitness benefit to production.
As genetic distance increases, however, so too does phe-
notypic and ecological divergence [8,9], and by exten-
sion resource competition. Toxin production is
therefore wasted when competing against genetically
very divergent strains because there is little resource
competition. In other words, toxin production becomes
costly because its benefits are diluted by the fact that
the producer and target strain do not compete with
each other.
This interpretation leads to the prediction that the
strength of antagonism should peak at intermediate
genetic distance. To test this prediction we studied the
interaction between two producer strains that produce a
multitude of bacteriocins and a range of sensitive ‘vic-
tim’ strains of varying genetic distance to the producers.
Specifically, we measured the ability of anticompetitor
toxins produced by two laboratory strains of Pseudomo-
nas aeruginosa, PA01 and PA14, to kill or inhibit 55
clinical strains of P. aeruginosa isolated from the lungs
of cystic fibrosis (CF) patients. Natural communities of
microbes associated with chronic infections such as
colonization of the cystic fibrosis lung are often highly
diverse [10-13]. We also measured the degree of ecolo-
gical similarity among strains, using commercially avail-
able BIOLOG plates that contain 95 different carbon
substrates, and show that ecological similarity can
decrease with genetic distance. This result is consistent
with the idea that toxin production is not favoured
among genetically divergent strains because of a lack of
resource competition.
Pyocins and Pseudomonas aeruginosa
P. aeruginosa produces a wide variety of toxins and
among the most interesting, in part because they are
known to be highly specific in their action, are bacterio-
cins called pyocins. They are costly to produce because
they are released by cell lysis of a fraction of the producer
population. Pyocins are proteinaceous compounds that
are classified into three groups (R-, F-, and S-type), with
multiple sub-types within each group that attach to dif-
ferent potential receptors in target strains [5,14,15]. PA01
is known to produce all three pyocins while PA14 pro-
duces only R- and F-type pyocins [4]. Genes coding for
production of all pyocins are located on the chromosome
and are clustered with genes coding for resistance to the
same pyocins. Genomic studies have suggested the pre-
sence of more pyocins [16-19], both from the S- and R-
types. In addition, a recently developed genome-mining
tool for bacteriocins has revealed the general existence of
yet to be characterized bacteriocins in several bacterial
species [20]. Other toxins produced by P. aeruginosa
include virulence factors such as exotoxin A, PCN and Y
as well as membrane vesicles [21-23].
The clinical strains in our study come from a multi-
centre Canadian study of the epidemiology of chronic
P. aeruginosa infections of CF patients [24], see Methods.
Chronic infection with P. aeruginosa occurs in 60-70% of
Canadian adults with CF [25]. After confirmation using
standard techniques that the isolates were P. aeruginosa
(Methods), genetic distance among all strains was esti-
mated by comparing banding patterns of a full genome
digest using pulsed field gel electrophoresis, PFGE
[26-30]. We also confirmed that genetic distance corre-
lates with the degree of overlap in resource use, mea-
sured by the ability of strains to metabolize 95 different
carbon substrates found on commercially available Biolog
plates.
Results and discussion
We measured the level of inhibition by anticompetitor
toxins by spotting a dilution series of a cell free extract
collected from 48 h old P. aeruginosa PA01 or PA14 cul-
ture onto a lawn of one of 55 different clinical isolates
growing on a solid surface. The natural isolates differ in
their genetic distance to the producing strain; genetic dis-
tance is quantified using full genome digests. The lowest
concentration of cell free extract that gave rise to inhibi-
tion of the clinical isolate was used to calculate the inhibi-
tion score (Figure 1) [14,15,31,32]. Figure 2 depicts the
level of inhibition by both PA01 and PA14 as a function of
genetic distance of toxin producing strain to the clinical
isolates.
Our results lend strong support to the idea that toxins
are most effective when active against genotypes of inter-
mediate genetic distance relative to the focal strain. The
relationship between inhibition and genetic distance is
unimodal, peaking at intermediate genetic distance for
both toxin producers PA01 and PA14. This result is con-
firmed more formally by noting that a quadratic model
with an internal maximum is a better descriptor of the
data than a linear model (Table 1; in the linear regressions,
the linear term is not significant), by the lower AIC
(Aikake’s Information Criterion) values for the quadratic
models than the linear models (Table 1) and by an F-ratio
test asking if adding the quadratic term provides a signifi-
cantly better fit than the linear model (PA01, F1,48 = 5.96,
P = 0.018; PA14, F1,42 = 17.56, P = 0.00014). We also
tested for the existence of an internal maximum in the
data using a Mitchell-Olds and Shaw (MOS) test (as
implemented in the R package vegan) following Mittel-
bach et al. (2001) [33]. This approach tests the null
hypothesis that a quadratic function, fitted to the data, has
no stationary point (either a maximum or minimum)
within the range provided. Our results reject this null
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hypothesis for both PA01 and PA14 at the P <0.1 level
(PA01: P = 0.072; PA14: P = 0.0006), the same criterion
used in Mittelbach et al. (2001) [33]. Since the sign of the
quadratic coefficient for both producer strains was nega-
tive, the results of the MOS test indicate the presence of a
statistically significant ‘hump’ within the range of genetic
distances examined. The evidence for an internal hump is
somewhat weaker for PA01 than PA14 but we note that
our test is conservative, as we have not included data on
the effectiveness of either strain at inhibiting itself. As
both of these values are zero (see Methods), including
these values would produce a much more pronounced
hump.
To verify that genetic distance correlates with resource
use, we measured the metabolic similarity of toxin pro-
ducing strains to the clinical isolates using Biolog plates
(see Methods). Metabolic profiles become more divergent
with increasing genetic distance, as expected, reflected in
the significantly negative linear relationship observed
between Jaccard distance and metabolic correlation
between pairs of strains (PA01: slope ± standard error =
-0.493 ± 0.213; multiple R2 = 0.098, t,49 = -2.312, P =
0.025; PA14: slope ± standard error = -0.644 ± 0.208,
multiple R2 = 0.164, t49 = -3.104, P = 0.0032). These
results lend support to the idea that genetic distance is
linked to ecological divergence. It is further notable that
inhibition score peaked at intermediate metabolic simila-
rities for both PA01 and PA14 but was statistically signif-
icant only for PA14 (see Additional file 1: Table S1 and
Additional file 2: Figure S1; F-ratio test on the fitting of
the quadratic term, PA01: F1,48 = 0.176, P = 0.68; PA14:
F1,42 = 7.00, P = 0.011).
It is not immediately obvious why we detected a signifi-
cant quadratic relationship between inhibition score and
metabolic similarity in one strain but not the other. One
possibility is that the Biolog plates we used here, which
provide profiles on carbon substrate metabolism, repre-
sent one of many possible dimensions along which ecolo-
gical divergence can proceed. Under this interpretation,
metabolic divergence in carbon substrate use may reflect
a correlated response to divergence in other ecologically
important factors such as ability to grow as a biofilm,
resistance to various stressors like pH, temperature, or
salinity, and possibly even predation, that we did not
measure. Thus we would still expect to see some rela-
tionship between metabolic similarity and genetic dis-
tance, as we did for PA01, even if this is not the sole
target of ecological divergence. There are any number of
other differences between PA01 and PA14 that could be
responsible for this difference. PA14 has a slightly larger
genome than PA01 (6.5 Mbp and 6.3 Mbp, respectively)
and contains a number of unique ‘pathogenicity islands’
that are thought to be associated with a generally
increased level of virulence in most hosts [34]. It also is
thought to produce only R- and F-type pyocins, whereas
PA01 produces all three types (R, F, and S) [4]. It is nota-
ble that S-pyocins differ from both R- and F-pyocins in
that they are oligopeptides whereas R- and F-pyocins are
both phage-like structures. Why or how the differences
Figure 1 Inhibition assay. Lawn of a Pseudomonas aeruginosa
natural isolate growing on the surface of an agar plate. Spots of
pyocin containing cell free extract from a laboratory strain of P.
aeruginosa PA01 were applied on the lawn at different dilutions.
The formation of clear zones is indicative of killing of the clinical
isolate. The highest dilution of cell free extract (thus containing the
lowest concentration of toxin) that inhibits the clinical isolate is a
measure of potency of the toxin. The inhibition score is the inverse
of the highest dilution that inhibits growth of the clinical isolate. In
this example, the spot marked A is non-diluted cell free extract;
spots B to F are serial 3-fold dilutions. The inverse of the dilution
factor of dilution D would be the inhibition score.
Figure 2 Inhibition by toxin containing cell free extract .
Inhibition of clinical isolates by toxins in cell free extract collected
from laboratory strains PA01 and PA14 as a function of genetic
distance (Jaccard similarity) between toxin producer and clinical
isolate. A unimodal non-linear relationship peaking at intermediate
Jaccard distance give best fit to the data (solid lines), better than a
linear fit, see text and Table 1.
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in genome content, size, or pyocin identity affects the
relationship between inhibition score and metabolic simi-
larity remains an open question, however.
What agents are responsible for killing in our experi-
ments? Bacteriophage were clearly not responsible. If
bacteriophage were causing the inhibition of clinical iso-
lates, they would be able to amplify themselves in an
exponential culture of the same clinical isolate. This was
not the case (see Methods). Three lines of evidence sug-
gest, rather, that toxic compounds such as pyocins or
exotoxins excreted by PA01 and PA14 are the main kill-
ing agent. The first is that PA01 and PA14 are not killed
by their own supernatant. Such a result is consistent with
the idea that the toxins are pyocins, as pyocin production
involves specific immunity genes that confer resistance
by preventing lysis in non-producing kin [4,5,35,36],
although it does not rule out the possibility that other
toxins with similar immunity properties are also involved.
If killing were associated with a non-specific toxic com-
pound such as some waste product, we would have
expected both producer strains to be susceptible to kill-
ing and killing would most likely also not depend on
genetic or metabolic similarity. Second, repeating the
inhibition assay with heat-treated supernatant eliminates
killing (Figure 3; both linear and quadratic regressions
are non-significant), providing strong support for the
idea that the killing compounds are proteins. Third, and
most interestingly, inhibition by PA01 is stronger, on
average, than that by PA14 (mean log inhibition score for
PA01 = 1.51; mean log inhibition score for PA14 = 0.95;
t-test, t93 = 6.05, P < 0.0001), a result that is likely due to
the fact that PA01 produces a larger array of pyocins
than PA14, including S-type pyocins [4].
Although these three lines of evidence point suggestively
to pyocins as being the main killing agent, we have not
conducted an explicit test of this hypothesis by, for exam-
ple, repeating our assays with pyocin knock-out strains.
Although it may be possible to conduct such a test by
focusing on the prtR/N regulator, which is thought to be a
global regulator of known pyocins [4,5], it is not clear that
such a test would be conclusive since a number of the
pyocins in both PA01 and PA14 have yet to be isolated
[18,19] and there may exist other exotoxins that behave in
similar ways to pyocins. Note also that knowing the
mechanism of killing, while of obvious interest, is in many
ways of secondary importance to the observation that the
Figure 3 Inhibition by heat treated cell free extract. Inhibition of
clinical isolates by heat treated cell free extract collected from
laboratory strains PA01 and PA14 as a function of genetic distance
(Jaccard similarity). No regression gave a significant fit to the data.
Table 1 Linear and quadratic regressions of inhibition of clinical isolates by sterile (non heat treated) cell free extract
of PA01 and PA14 cultures as function of genetic distance (Figure 2)
Source df Value St Error t P-value Multiple R2 AIC
PA01 Linear model 0.072 0.059 90.91
Intercept 1 3.27 0.969 3.38 0.0014
Linear term 1 -2.41 1.31 -1.84 0.072
Residual SE 53 0.55
PA01 Quadratic model 0.010 0.160 86.94
Intercept 1 -17.00 8.81 -2.08 0.043
Linear term 1 53.94 22.61 2.38 0.021
Quadratic term 1 -38.89 15.58 -2.50 0.016
Residual SE 52 0.53
PA14 Linear model 0.15 0.044 39.80
Intercept 1 1.99 0.71 2.81 0.0072
Linear term 1 -1.45 0.98 -1.48 0.15
Residual SE 47 0.36
PA14 Quadratic model < 0.0001 0.345 26.08
Intercept 1 -37.51 8.62 -4.35 0.0001
Linear term 1 109.8 24.23 4.53 < 0.0001
Quadratic term 1 -77.88 16.95 -4.59 < 0.0001
Residual SE 46 0.30
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effectiveness of killing depends in a regular way on genetic
distance, at least in the strains we have studied here.
Our main result is that the strength of antagonistic
interactions peak at intermediate genetic distance. This
pattern is strikingly similar to that expected from theo-
retical [37] and experimental [38,39] kin selection mod-
els for selection using mixed populations of two strains
at various ratios to adjust relatedness and considering
one bacteriocin and one immunity protein. These mod-
els have emphasized how the cost of bacteriocin produc-
tion is affected by the social environment: bacteriocin
production is not favored when producers are both
common, because the majority of competitors are kin
and so immune to the bacteriocin, and rare, because
there are now too few kin to enjoy the benefits of the
extra resources. This is clearly not an appropriate inter-
pretation of our results because we did not manipulate
the frequency of producers and non-producers in our
experimental system to adjust relatedness, as Inglis et al.
[38] have done using degree of kinship as a measure of
relatedness.
Rather, our results provide some evidence consistent
with the idea that ecological divergence may be important
in mediating social interactions. It is notable that the
explanation for the ineffectiveness of toxins at inhibiting
closely related genotypes (i.e. short genetic distance) in
our experiment is likely similar to that in kin selection
models: they share a degree of immunity to each other’s
toxins. However, the ineffectiveness of toxins against dis-
tantly related genotypes in our system is probably not
directly tied to kin selection. Because increasing genetic
divergence is accompanied by reduced overlap in resource
use, distantly related genotypes are unlikely to compete for
similar resources and so the resources liberated through
antagonism are therefore unlikely to benefit the producer
[8,40]. The production of antagonistic traits such as bac-
teriocins in this situation is therefore likely to be costly
and so selection should lead to decreased levels of antag-
onism. Our observation of decreased antagonism among
distantly related strains, at least for PA14, is consistent
with this interpretation.
This interpretation is in accordance with the idea that
the evolution of specific antagonism against conspecifics,
as is often observed for bacteriocins, could evolve as a
direct response to intraspecific resource competition and
is consistent with models describing how fitness varies as
a function of the strength of resource competition
between types: the strength of resource competition, and
so the loss of fitness, is highest when resource overlap is
intermediate [41]. To the extent that the opportunity or
intensity of resource competition is enhanced through
the physical proximity of co-occurring strains in a given
habitat [42], such as a CF lung, then this may further pro-
mote the evolution of antagonistic interactions such as
those mediated by bacteriocins. It remains to be seen
whether our results are specific to the strains we used in
this study or whether they apply more broadly to non-CF
strains of P. aeruginosa or other species. This will be an
important avenue for future research.
It is not possible with our data to distinguish the specific
mechanisms causing variation in toxin susceptibility. If
bacteriocins are indeed responsible for killing, then one
possibility is that selection targets the total amount of
bacteriocin production or the efficiency with which bacter-
iocins inhibit or kill their victims. It is also possible that
the target of selection is the number of receptor sites for
bacteriocins in target strains. Deciding among these alter-
natives requires follow-up experiments that focus on find-
ing the evolutionary origin of bacteriocins using direct
competition experiments of producer stains and several
target strains to ask under what conditions and by what
mechanism bacteriocins aid producer populations to
invade populations of sensitive strains [43]. These experi-
ments would however be very elaborate since the effect of
many complicating factors such as frequency dependence,
cross-feeding, the viscosity of the environment and exact
costs of producing bacteriocins would have to be deter-
mined for the interaction of the producer and each target
strain. It is even possible that the high specificity of bacter-
iocins results from their having evolved initially as a by-
product of selection for fertility-recognition systems such
as conjugation that were later co-opted for use as bacterio-
cidal agents [49]. Investigating the relationship between
bacteriocin diversity and conjugation frequency or recom-
bination could help shed some light on this issue.
Our results have important implications for under-
standing of the dynamics of infection in clinical settings.
We have firmly established that toxic compounds with
high specificity mediate bacterial interactions as antago-
nistic agents, for instance in structuring pathogen popu-
lations in patients with a mixed P. aeruginosa infection
[12]. Social evolution theory predicts that selection for
antagonism among pathogenic strains should be accom-
panied by reduced virulence to the host. The conse-
quences of P. aeruginosa infection on patient morbidity
and mortality may therefore depend to some extent on
the particular strains present. Furthermore, it is notable
that recent research on CF patients from Ontario sug-
gests that 25% of Ontario patients who are infected with
P. aeruginosa are infected with one of two predominant
epidemic strains. It may be that the predominance of
these epidemic strains is due to the production of specific
antagonistic agents such as pyocins [13]. This is an intri-
guing hypothesis that awaits further testing. As a start,
we have confirmed that three of our clinical isolates pro-
duce toxic substances that kill or inhibit other clinical
isolates (data not shown). Thus the antagonistic interac-
tions we have studied here do happen among clinical
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isolates and are not just the consequence of using strains
PA01 and PA14 as producers in our study [13].
Understanding the way toxins such as pyocins kill
P. aeruginosa strains, and how this is modulated by
genetic relatedness, may also provide insight into the
development of novel therapeutic interventions, for
example by evolving pyocins specifically against strains
that predominate in infections. They can thus be consid-
ered designer drugs [7,23,44,45] and will be a much
more direct agent to treatment of the disease than the
current practice of using broad spectrum antibiotics
against which wide spread resistance exists [46]. Inter-
estingly, pyocins are not new in a clinical setting: it has
been shown that pyocins slow down the development of
several forms of cancer in mammalian cells [47]. Also,
membrane vesicles produced by P. aeruginosa have been
suggested as novel therapeutic agents [23]. However
they may be even more effective when used in a tar-
geted way against known infections. The similarity
between strains can then be used as a predictor of the
intensity of the antagonistic interaction and thus the
effectiveness of the pyocin.
Conclusions
Using clinical and laboratory strains of Pseudomonas
aeruginosa, we found that the level of antagonism
between toxin producing and target strains is maximal
at intermediate genetic and metabolic similarity between
producer and target strain. We explained this result in
the context of resource competition: resource competi-
tion is expected to be maximal for strains that are not
your kin but also not completely unrelated since those
strains do not share the same need for resources and
are less likely to be a competitor. Our results suggest
that the importance of antagonism and perhaps other
social interactions between bacteria are modulated by
the strength of resource competition.
Methods
Bacterial strains and culture conditions
We used standard laboratory strains Pseudomonas aerugi-
nosa strains PA01 and PA14 and 55 natural P. aeruginosa
isolates collected from cystic fibrosis patients. Infection
with P. aeruginosa is associated with increased morbidity
and mortality for CF patients, irrespective of lung function.
Both population-based and case-control studies have
demonstrated that infection with P. aeruginosa bacteria
appears to be an independent prognostic factor that car-
ries with it an increased risk of death [38,40]. Strains used
here were isolated from sputum samples obtained from
multiple patients all of whom had chronic endobronchial
infections. Clinical P. aeruginosa isolates were collected
between September 2005 and June 2008 from adult
patients with confirmed cystic fibrosis who attended one
of the seven Ontario adult cystic fibrosis clinics or who
attended smaller outreach clinics [24]. These 7 clinics pro-
vide secondary and tertiary care to more than 97% of all
CF patients in Ontario. Patients were included in the
study if they were ≥ 18 years of age, able to spontaneously
produce sputum, and if they had a confirmed diagnosis of
cystic fibrosis (a sweat chloride value higher than
60 mmol/litre and/or 2 disease-causing mutations). The
research ethics board (The Ottawa Hospital Research
Ethics Board) of all the participating centers approved the
study, and all participants provided written informed con-
sent. Patients provided sputum samples which were cour-
iered on ice to the central laboratory in Ottawa. To detect
P. aeruginosa and other bacterial pathogens, sputum was
plated onto the following selective and nonselective media:
Columbia blood agar plate (PML), MacConkey agar plate
(PML), and Pseudomonas aeruginosa selective agar plate
(Oxoid). Plates were incubated at 35°C for 48 hours and
P. aeruginosa colonies were identified by oxidase testing,
TSI, arginine and growth at 42°C. If P. aeruginosa was iso-
lated, then two distinct P. aeruginosa colony morphotypes
from each sputum were worked up for molecular typing,
and five P. aeruginosa isolates derived from each sputum
were frozen at -70°C.
To prepare for inhibition assays, strains were streaked
from frozen on Pseudomonas Isolation Agar (Difco). Sin-
gle colonies were used to inoculate liquid LB (bacto-tryp-
tone 10 g, yeast extract 5 g, NaCl 10 g, dH2O 1000 ml)
and incubated under aerobic shaken conditions (150 rpm)
at 37°C for 24 to 48 h to yield dense cultures.
Estimation of genetic distance
Genetic distance was estimated by comparing molecular
genotypes of each P. aeruginosa isolate generated through
pulsed-field gel electrophoresis (PFGE). PFGE is a well-
accepted method [26,30] that differs from multi-locus
sequence typing (MLST)-based approaches in that it
includes the entire genome rather than just seven house-
keeping genes. MLST profiling of our strains using seven
housekeeping genes showed high similarity for those
genes; what we would expect since they were all classified
as P. aeruginosa. Studies [27] have shown that PFGE is
more accurate when typing very closely related strains
from the same species. To generate PFGE profiles, geno-
mic DNA was prepared by a modification of a previously
described method [48]. P. aeruginosa isolates were grown
overnight at 37°C on Tryptone Soya Agar plates contain-
ing 5% sheep’s blood. Colonies were suspended in buffer
(1 M NaCl, 10 mM Tris-HCl [pH 7.6]) and 70 μL of the
suspension was mixed with an equal amount of 1.6% low
melt agarose (Cambrex, East Rutherford, NJ). This mixture
was pipetted into a plug mold (Bio-Rad, Hercules, CA)
and allowed to solidify at room temperature. Plugs were
added to plug lysis solution (1 M NaCl, 100 mM EDTA
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[pH 7.5], 0.5% Brij-58, 0.5% Sarcosyl, 0.2% Deoxycholate, 6
mM Tris-HCl [pH 7.6], 1 mg/mL Lysozyme powder, 20
μg/ml RNase) and incubated for 4 h at 37°C with shaking.
Plugs were then placed in Proteinase K solution (0.5 M
EDTA [pH 9-9.5], 1% Sarcosyl, 50 μg/ml Proteinase K)
and incubated overnight at 50°C with shaking. Plugs were
washed 3-4 times with TE buffer (10 mM Tris-HCl [pH
7.5], 0.1 mM EDTA [pH 7.5]) at 37°C and then stored at
4°C. DNA in a 2-3 mm piece of the gel plug was restricted
using 20 U SpeI (New England Biolabs, Ipswich, MA) in a
reaction volume of 0.2 mL at 37°C. The digestion products
were melted and electrophoresis was performed on a 1.0%
agarose gel, in 0.5X TBE (VWR International Ltd, Missis-
sauga, ON), using a CHEF DR III apparatus (Bio-Rad,
Hercules, CA). Electrophoresis conditions were as follows:
20 h at 6 V/cm with switch times of 5 s to 45 s with a lin-
ear ramping factor. Using the ladder, all banding patterns
were inspected for the presence/absence of a visible band
at 51 locations. These presence/absence data were used to
calculate the genetic distance by calculating the Jaccard
similarity (Jaccard distance equals 1- Jaccard similarity) of




where Mij represents the total num-
ber of positions where bands are present (i = j = 1), or
when one strain or the other possesses a band (i ≠ j).
Other measures of similarity such as the Hamming dis-
tance, Dice coefficient and correlation coefficient gave
similar qualitative results. We used R software (version
2.6.1) to calculate distance measures and for all statistical
analyses.
Estimation of metabolic similarity
Resource use was measured using BIOLOG GN2 plates
that consist of different wells with a total of 95 different
carbon sources. All 55 clinical isolates and strains
P. aeruginosa PA01 and PA14 were grown up in liquid
LB medium. From a dense stationary phase culture,
20 μl was added to 20 ml of a minimal salts medium
(Na2HPO4 6.7 g, KH2PO4 3 g, NaCl 0.5 g, NH4Cl 1.0 g,
1000 ml dH2O) which was used to inoculate the Biolog
plates after a 2 h starvation period. For clinical isolates, 1
Biolog plate was used, for P. aeruginosa PA01 and PA14
three replicate plates were used. Right after inoculation
and after 48 h of incubation at 37°C, the OD (590 nm)
was measured of all wells. The difference in OD at the
two time points is a measure of how well a given strain is
able to use a given resource. To quantify the metabolic
similarity, we calculated the correlation coefficient
between the OD values of the different strains.
Inhibition assays
The strains P. aeruginosa PA01 and PA14 were assayed
for their ability to produce toxic compounds that can
inhibit the natural P. aeruginosa isolates collected from
CF patients using a method adopted from Jacob 1954
[14]. Bacterial cells of dense LB cultures (48 h old) of
PA01 and PA14 were spun down in a centrifuge. Super-
natant was collected and filtered (0.20 μm) and serially
diluted in minimal salts medium [14]. For the assay ask-
ing if proteinaceous compounds are responsible for kill-
ing, the sterile supernatant was heated for 15 s at 100°C.
0.5 ml of a dense culture of a natural isolate was added
to 3 ml of molten semi solid LB (bacto-tryptone 10 g,
yeast extract 5 g, NaCl 10 g, agar 7 g, 1000 ml dH2O)
and poured out over the surface of a Petri dish contain-
ing minimal salts agar (as described above with 10 g of
agar added) as an overlay. A dilution series of either
non-heat treated or heat treated sterile supernatant was
spotted on top of the layer of natural isolate, up to 11
spots of 15 μl were spotted on a single Petri dish with
overlay. Cultures were incubated for 48 h at 37°C. The
inverse of the highest dilution of sterile supernatant giv-
ing rise to inhibition was defined as the inhibition score,
which is effectively a measure of the minimal inhibitory
concentration (MIC). The inhibition scores were log
transformed prior to analysis. No inhibition was
observed when spotting sterile PA01or PA14 superna-
tant on top of an overlay with the same strain.
To exclude the possibility that bacteriophage are
responsible for the observed inhibition, we performed a
one-step growth assay as follows. The zones of inhibi-
tion formed on overlays of clinical isolates were trans-
ferred to an exponential liquid culture of growing cells
of the same clinical isolate. After 24 h, cell free extract
was prepared and spotted onto a layer of the clinical
isolate. A resulting clear zone of inhibition would be
indicative of the presence of bacteriophage because a 24
h liquid culture of clinical isolate should contain even
more bacteriophage than the initial culture since bacter-
iophage are able to reproduce with the appropriate host
cells present. We found no evidence for the presence of
bacteriophage.
Additional material
Additional file 1: Table S1. Inhibition of clinical isolates by toxins in cell
free extract collected from laboratory strains PA01 and PA14 as a
function of metabolic similarity (correlation coefficient) between toxin
producer and clinical isolate based on BIOLOG profiles. A unimodal non-
linear relationship peaking at intermediate metabolic similarity give best
fit to the data for producer PA14 (solid lines), better than a linear fit; for
PA01 no such relationship was found. See text and Supplemental Table.
Additional file 2: Figure S1. Inhibition of clinical isolates by toxins in
cell free extract collected from laboratory strains PA01 and PA14 as a
function of metabolic similarity (correlation coefficient) between toxin
producer and clinical isolate based on BIOLOG profiles. A unimodal non-
linear relationship peaking at intermediate metabolic similarity give best
fit to the data for producer PA14 (solid lines), better than a linear fit; for
PA01 no such relationship was found. See text and Supplemental Table.
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